Scilex (SCLX) Stock Price, News & Analysis

Company Overview

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.

Key Stats

• Today's Range: $0.95 to $1.01
• 50-Day Range: $0.79 to $1.15
• 52-Week Range: $0.73 to $2.63
• Volume: 2.08 million shs
• Average Volume: 2.28 million shs
• Market Capitalization: $186.30 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.33
• Consensus Rating: Buy

Scilex Stock Analysis - MarketRank™

Scilex scored higher than 57% of companies evaluated by MarketBeat, and ranked 503rd out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Scilex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Scilex has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Scilex are expected to grow in the coming year, from ($0.75) to ($0.39) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Scilex is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Scilex is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.46% of the float of Scilex has been sold short.

Short Interest Ratio / Days to Cover

Scilex has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.

Change versus previous month

Short interest in Scilex has recently increased by 9.75%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Scilex does not currently pay a dividend.

Dividend Growth

Scilex does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

10.46% of the float of Scilex has been sold short.

Short Interest Ratio / Days to Cover

Scilex has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.

Change versus previous month

Short interest in Scilex has recently increased by 9.75%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 0.85

News Sentiment

Scilex has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Scilex this week, compared to 2 articles on an average week.

Search Interest

5 people have searched for SCLX on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.

MarketBeat Follows

8 people have added Scilex to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Scilex insiders have bought more of their company's stock than they have sold. Specifically, they have bought $95,234.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 8.73% of the stock of Scilex is held by insiders.

Percentage Held by Institutions

69.67% of the stock of Scilex is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SCLX Stock Analysis - Frequently Asked Questions

How have SCLX shares performed this year?

Scilex's stock was trading at $2.04 on January 1st, 2024. Since then, SCLX stock has decreased by 52.4% and is now trading at $0.9714.
View the best growth stocks for 2024 here.

How were Scilex's earnings last quarter?

Scilex Holding (NASDAQ:SCLX) announced its earnings results on Tuesday, August, 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.02. The firm had revenue of $16.37 million for the quarter, compared to analysts' expectations of $13.17 million.

Who are Scilex's major shareholders?

Top institutional shareholders of Scilex include Donald L. Hagan LLC (0.07%). Insiders that own company stock include Henry Ji, Jaisim Shah, Jay Chun, Yue Alexander Wu and Stephen Hoi Ma.
View institutional ownership trends.

How do I buy shares of Scilex?

Shares of SCLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Scilex own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Scilex investors own include Rigetti Computing (RGTI), Pfizer (PFE), BioNTech (BNTX), Hertz Global (HTZ), Barrick Gold (GOLD), Nikola (NKLA) and BlackBerry (BB).

Company Calendar

• Last Earnings: 8/13/2024
• Today: 11/02/2024
• Next Earnings (Estimated): 11/12/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SCLX
• CUSIP: N/A
• CIK: 1820190
• Web: www.scilexholding.com
• Phone: 650-516-4310
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $11.33
• High Stock Price Target: $14.00
• Low Stock Price Target: $7.00
• Potential Upside/Downside: +1,066.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.43)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-114,330,000.00
• Net Margins: -233.88%
• Pretax Margin: -233.86%
• Return on Equity: N/A
• Return on Assets: -111.82%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.20
• Quick Ratio: 0.19

Sales & Book Value

• Annual Sales: $46.74 million
• Price / Sales: 3.99
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.10) per share
• Price / Book: -0.88

Miscellaneous

• Outstanding Shares: 191,790,000
• Free Float: 175,048,000
• Market Cap: $186.30 million
• Optionable: Optionable
• Beta: 1.14